The Patent Finder

Poniard Pharmaceuticals, Inc.

Also on record
Records under this name other than patents Poniard Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Poniard Pharmaceuticals, Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,505,719Synthesis and use of kinase inhibitors
Formerly held
Lapsed on the fee record
Ended Nov 29, 2020 · USPTO record
Lapsed on the fee recordEnded Nov 29, 2020USPTO record
US 9,375,402Oral formulations of kinase inhibitors
Formerly held
Lapsed on the fee record
Ended Jun 28, 2020 · USPTO record
Lapsed on the fee recordEnded Jun 28, 2020USPTO record
US 8,178,564Use of Picoplatin to Treat Colorectal Cancer
Formerly held
Lapsed on the fee record
Ended May 15, 2020 · Low confidence
Lapsed on the fee recordEnded May 15, 2020Low confidence
US 8,173,686Use of Picoplatin to Treat Colorectal Cancer
Formerly held
Lapsed on the fee record
Ended May 8, 2020 · Low confidence
Lapsed on the fee recordEnded May 8, 2020Low confidence
US 8,168,661Use of Picoplatin to Treat Colorectal Cancer
Formerly held
Lapsed on the fee record
Ended May 1, 2020 · Low confidence
Lapsed on the fee recordEnded May 1, 2020Low confidence
US 8,168,662Use of Picoplatin to Treat Colorectal Cancer
Formerly held
Lapsed on the fee record
Ended May 1, 2020 · Low confidence
Lapsed on the fee recordEnded May 1, 2020Low confidence
US 6,117,551Carbon fiber prepreg, and a production process thereof
Term ended
Term ended Aug 11, 2018 · USPTO record
Term endedTerm ended Aug 11, 2018USPTO record
US 6,251,920Prevention and treatment of cardiovascular pathologies
Term ended
Term ended May 21, 2018 · USPTO record
Term endedTerm ended May 21, 2018USPTO record
US 6,197,789Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
Term ended
Term ended Dec 5, 2017 · USPTO record
Term endedTerm ended Dec 5, 2017USPTO record
US 6,166,090Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
Term ended
Term ended Nov 6, 2017 · USPTO record
Term endedTerm ended Nov 6, 2017USPTO record
10 of 52 patents shown.
Pro members see all 52.
Pro members: see all 52 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited